Fixed Competitive Price Ticagrelor Classification - Venetoclax 1257044-40-8 – CPF
Fixed Competitive Price Ticagrelor Classification - Venetoclax 1257044-40-8 – CPF Detail:
维奈妥拉 | Venetoclax | 1257044-40-8 | In-House |
VCL-6A | 98549-88-3 | In-House | |
VCL-7A | 1235865-75-4 | In-House | |
VCLM2 | 1228780-72-0 | In-House | |
VCLM2-2HCl | 1628047-87-9 | In-House | |
VCLM3 | 1228779-96-1 | In-House |
Generic Name: venetoclax (ven ET oh klax)
Brand Name: Venclexta, Venclexta Starting Pack
Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.
Venetoclax is used in combination with azacitidine, decitabine, or cytarabine to treat acute myeloid leukemia. This combination is for use in adults who are 75 years or older, or who cannot use standard chemotherapy due to other medical conditions.
Venetoclax is sometimes given after other treatments have failed.
Venetoclax may also be used for purposes not listed in this medication guide.
Description
Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy.
In Vitro
Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC50=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC50=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC50=3 nM) but is much less effective against BCL-XL-BCL-XS (EC50=2.2 μM) or MCL-1-NOXA complexes.
After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGImax) of 47% (P<0.001) and tumor growth delay (TGD) of 26% (P<0.05)[1].
Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days results in a significant reduction of leukemic burden.
Storage
Powder |
-20°C |
3 years |
4°C |
2 years | |
In solvent |
-80°C |
6 months |
-20°C |
1 month |
Chemical structure
Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.
Advanced international quality management system has laid solid foundation for sales.
Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.
Professional Regulatory Affairs team supports the quality demands during the application and registration.
VIEW MORE
VIEW MORE
International cooperation
Domestic cooperation
Product detail pictures:
Related Product Guide:
Bear "Customer first, Excellent first" in mind, we operate closely with our customers and supply them with efficient and expert services for Fixed Competitive Price Ticagrelor Classification - Venetoclax 1257044-40-8 – CPF , The product will supply to all over the world, such as: US, Greek, Doha, Since always, we adhering to the "open and fair, share to get, the pursuit of excellence, and creation of value"values, adhere to the"integrity and efficient, trade-oriented, best way , best valve" business philosophy. Together with our all over the world have branches and partners to develop new business areas, maximum common values. We sincerely welcome and together we share in global resources, opening up new career together with the chapter.
By Elsie from Iran - 2018.06.21 17:11
The company can keep up with the changes in this industry market, product updates fast and the price is cheap, this is our second cooperation, it's good.
By Modesty from Istanbul - 2017.06.22 12:49